Palbociclib is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, Palbocap works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast.
INDICATION
Palbocap is a prescription medicine used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) in combination with:
An aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause.
Fulvestrant in women with disease progression following hormonal therapy.
